A Phase 4 interventional study of Infliximab in Inflammatory Bowel Diseases, sponsored by IRCCS Burlo Garofolo. Recruiting at 1 site in Italy. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-08-18.
Sponsored by IRCCS Burlo Garofolo · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing infliximab in Inflammatory Bowel Diseases — 6 open to participants now, 7 under way, none of them phase 3. Infliximab · Inflammatory Bowel Diseases.
Among the 20 studies testing infliximab in Inflammatory Bowel Diseases, this one is the 10th largest by planned enrollment, is one of 3 that started in 2022, is one of 10 in phase 4, and was the 14th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →6 of the 20 studies testing infliximab in Inflammatory Bowel Diseases are open now, in 6 countries. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 18–64
Pontificia Universidad Catolica de Chile · Sites in Chile
Ages 18–75
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Sites in Belgium
Ages 18+
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
Chinese Medical Association
Ages 18–75
By country, each count listing its studies:
Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 3 · Phase 4 10
First in 2006; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is above the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 83 across the 20 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
IRCCS Burlo Garofolo is the lead sponsor of 89 studies on the registry; 32 are open to participants now.
IRCCS Burlo Garofolo has 3 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies testing infliximab in Inflammatory Bowel Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06758024Pontificia Universidad Catolica de ChilePROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel Disease | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing infliximab in Inflammatory Bowel Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess whether a proactive therapeutic drug monitoring strategy, introduced early during treatment, improves Infliximab (IFX) durability, efficacy and safety in children and young adults with inflammatory bowel disease. Patients with an indication to receive IFX, based on current clinical practice recommendations, will receive the drug either based on IFX concentrations determined before every IFX infusion, starting from the third infusion, or at standard dosing. Approximately 90 patients will be included in this research study. Patients enrolled will be in the study for approximately 12 months.
Inflammatory Bowel Disease (IBD) are relapsing disorders with progressive bowel damage leading to long-term disability.
Infliximab (IFX), is a highly effective and commonly used biologic in IBD. However, up to 40% of patients do not respond to treatment or lose response over time. Low-serum IFX concentrations and the development of antibodies to IFX (ATI) are two major factors affecting IFX efficacy, durability and safety. Standard IFX dose is administered as an IV (in the vein) infusion at 5 mg/kg in a 0, 2, and 6 weeks induction regimen followed by a maintenance regimen with infusions every 8 weeks. This standard dosing is extrapolated from adult studies. IFX has a highly variable pharmacokinetic and pharmacodynamics that is dependent on body weight, disease extent, levels of inflammation and the presence of ATI. In children and young adults with IBD all these factors often result in low-serum IFX concentrations.
Proactive therapeutic drug monitoring, consists in the measurement of drug concentrations on patient's blood, in order to adjust the following administrations (dosing or interval) and maintain a desired concentration of the medication in the body.
This study seeks to determine whether a proactive therapeutic drug monitoring strategy can improve IFX durability, efficacy and safety in children and young adults with IBD. The study will involve approximately 90 patients, aged 6 to 17 years, with IBD. All the patients enrolled in the study will receive IFX at 5mg/kg at week 0, 2 and 6. At week 6 patients will be randomly assigned to receive IFX treatment either based on IFX concentrations determined before every IFX infusion (intervention group) or at standard dosing (control group). Patients will participate in the study for 54 weeks (approximately 12 months) or until IFX discontinuation. During the study, patients will visit the study center at the time of every IFX infusion or in case of disease flares.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6. From week 6, the infusion interval will be adjusted based on pre-infusion IFX concentrations to target a trough level grater or equal to (\>=) 5 mcg/ml (\> 10 μg/ml in patients with perianal disease). For IFX concentrations below target, the infusion interval will be shortened (minimum interval 2 weeks). IFX dose increase will be performed as a second step.
Drug: Infliximab
Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6 followed by 5mg/kg infusions every 8 weeks.
Drug: Infliximab
Infliximab
Frequency of IFX discontinuation or need for treatment intensification due to non-response or LOR during the first year of treatment.
Composite outcome. Treatment intensification is defined as adjunction of rescue therapies, including corticosteroids systemic or topical, azathioprine (AZA), methotrexate (MTX), 5-aminosalicylate (5-ASA) systemic or topical, or rescue IFX escalation or surgery; treatment response is defined as a decrease in Pediatric Crohn's Disease Activity Index (PCDAI) by 12.5 point or in Pediatric Ulcerative Colitis Activity Index (PUCAI) by 10 points with decrease in C reactive protein (CRP) by 50% after induction, evaluated between 12-14 weeks; loss of response (LOR) is defined as PCDAI \>= 10 or PUCAI \> 10 with CRP \> 0.5mg/dl and/or fecal calprotectin (FC) \>250 microg/g in a patient who previously responded to induction treatment.
Time frame: 54 weeks
Cumulative probability of IFX discontinuation
Time to IFX discontinuation
Time frame: 54 weeks
Cumulative probability of Loss of Response
Time to Loss of Response (LOR), with LOR defined as PCDAI \>= 10 or PUCAI \> 10 with CRP \> 0.5 mg/dl and/or FC \>250 microg/g in a patient who previously responded to induction treatment.
Time frame: 54 weeks
Frequency of subtherapeutic IFX concentrations
Subtherapeutic IFX concentration is defined as IFX concentration at trough \< 5 microg/ml (or \<10 microg/ml in perianal CD) during maintenance treatment.
Time frame: 54 weeks
Frequency of Anti-Infliximab Antibodies
Evaluation of Anti-Infliximab Antibodies
Time frame: 54 weeks
Frequency of infusion reactions
Infusion reactions are defined as reactions that develop during the course of the infusion or within 1-2h of its completion.
Time frame: 54 weeks
Frequency of endoscopic remission
Endoscopic remission is defined in patients with Crohn's Disease as a Simple Endoscopic score for Crohn's Disease (SES-CD score) less than or equal to (\<=) 2 and in patients with Ulcerative Colitis as a Mayo sub-score \<= 1
Time frame: 54 weeks
Frequency of patients with treatment response at the end of induction between 12 and 14 weeks
Treatment response is defined as a decrease in PCDAI by 12.5 point or in PUCAI by 10 points with decrease in CRP by 50% compared to baseline
Time frame: Week 14
Frequency of patients with clinical remission at 14 weeks
Clinical remission is defined as PCDAI \<10 or PUCAI \<10
Time frame: Week 14
Frequency of clinical and biochemical remission at week 14
Clinical and Biochemical remission is defined as PCDAI \<10 or PUCAI \<10 with CRP \< 0.5 mg/dl and FC \< 250 microg/g
Time frame: Week 14
Started Mar 2022 (actual). Primary completion is estimated for Jan 2024, 22 months after the start.
Of 33 non-industry phase 4 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 63. This study's planned 22 months is below that.
Counting every sponsor, half of 38 studies reached it within 38 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infliximab
IRCCS Burlo Garofolo